Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 72

Sort by

Sort Order Select

Journal Articles

In-Depth Immune and Metabolic Profiling of GAIA/CLL13 Patients to Uncover Treatment-Specific Changes to the T-Cell Compartment

Blood (2024) 144 (Supplement 1): 1846.

https://doi.org/10.1182/blood-2024-209692

Published: 2024

Journal Articles

Improved Innate Immune Function upon Preemptive Short-Term Acalabrutinib and Venetoclax in Newly Diagnosed CLL Patients with High Risk of Infections: Translational Findings from the Prevent-Acall Clinical Trial

Rebecca Svanberg Teglgaard, Rudi Agius, Caspar da Cunha-Bang, Tereza Faitova, Christian Brieghel, Hans Jakob Hartling, Hanne Vibeke Marquart, Robert Schou Pedersen, Christian Bjørn Poulsen, Mark-David Levin, Fransien De Boer, Koen de Heer, Rikke Kragh Lauridsen, Joanne Reekie, Anders Österborg, Jeanette Lundin, Magdalena Kättström, Sisse Rye Ostrowski, Carsten Utoft Niemann

Blood (2024) 144 (Supplement 1): 4609.

https://doi.org/10.1182/blood-2024-204985

Published: 2024

Journal Articles

Informative Censoring in Randomized First-Line Trials of Chronic Lymphocytic Leukemia

Blood (2024) 144 (Supplement 1): 6799.

https://doi.org/10.1182/blood-2024-203673

Published: 2024

Journal Articles

Telomere Length Associations with Characteristics and Outcome in Patients Treated with Venetoclax-Based First-Line Combinations in the GAIA/CLL13 Study

Blood (2024) 144 (Supplement 1): 4626.

https://doi.org/10.1182/blood-2024-204852

Published: 2024

Journal Articles

Ibrutinib-Rituximab Is Superior to Rituximab-Chemotherapy in Previously Untreated Older Mantle Cell Lymphoma Patients: Results from the International Randomised Controlled Trial, Enrich

Blood (2024) 144 (Supplement 1): 235.

https://doi.org/10.1182/blood-2024-199710

Published: 2024

Journal Articles

Improved Efficacy with Response- and MRD-Guided Ibrutinib-Obinutuzumab (IO) Intensification after Ibrutinib-Venetoclax (IV) in First Line Chronic Lymphocytic Leukemia (CLL) Patients: Primary Analysis of the HOVON 158/Next STEP Phase 2 Trial

Blood (2024) 144 (Supplement 1): 1013.

https://doi.org/10.1182/blood-2024-207452

Published: 2024

Journal Articles

Acalabrutinib and Rituximab in Elderly Patients with Newly Diagnosed Mantle Cell Lymphoma Including a Matched Population-Based External Comparator- the Nordic Lymphoma Group NLG-MCL8 (ALTAMIRA) Phase II Trial

Mats Jerkeman, Karin Fahl Wader, Ingrid Glimelius, Annika Pasanen, Won Seog Kim, Louise Krüger Hansen, Jon Riise, Martin Hutchings, Hashim Hussein Elhussein, Carsten Utoft Niemann, Rasmus Rask Kragh Jørgensen, Tarec Christoffer El-Galaly, Mats Ehinger, Klaus Beiske, Rose-Marie Amini, Michael Boe Møller, Marja-Liisa Karjalainen-Lindsberg, Jacob Haaber Christensen

Blood (2024) 144 (Supplement 1): 747.

https://doi.org/10.1182/blood-2024-192939

Published: 2024

Journal Articles

First-Line Ibrutinib Plus Venetoclax Vs Chlorambucil Plus Obinutuzumab in Elderly or Comorbid Patients (Pts) with Chronic Lymphocytic Leukemia (CLL): Glow Study 64-Month Follow-up (FU) and Adverse Event (AE)-Free Progression-Free Survival (PFS) Analysis

Blood (2024) 144 (Supplement 1): 1871.

https://doi.org/10.1182/blood-2024-203269

Published: 2024

Journal Articles

Machine Learning for Prediction of Serious Infections in Patients with Treatment-Naïve Lymphoma; A Population-Based Study of 701 Patients from the North Denmark Region

Alexander Fuglkjær, Deniz Kenan Kilic, Mathias Holmsgaard Eskesen, Laurids Østergaard Poulsen, Carsten Utoft Niemann, Paw Jensen, Kirstine Kobberøe Søgaard, Mikkel Werling, Frederik Christensen, Mikkel Runason Simonsen, Izabela Ewa Nielsen, Tarec Christoffer El-Galaly

Blood (2024) 144 (Supplement 1): 3605.

https://doi.org/10.1182/blood-2024-193940

Published: 2024

Journal Articles

Safety of Venetoclax Ramp-up before CD20 Antibody Administration in Chronic Lymphocytic Leukemia

Emelie Curovic Rotbain, Mikkel Werling, Casper Møller Frederiksen, Christian Bjørn Poulsen, Martin Hutchings, Caspar Da Cunha-Bang, Carsten Utoft Niemann

Blood (2024) 144 (Supplement 1): 3243.

https://doi.org/10.1182/blood-2024-203172

Published: 2024

Journal Articles

Excellent Clinical Outcomes in Deeply Mutated IGHV Chronic Lymphocytic Leukemia upon Fludarabine and Cyclophosphamide Plus Rituximab

Andreas Katsimigas, Lone Bredo Pedersen, Thure Haunstrup, Thor Hoeyer, Rikke Olsen, Michael Boe Møller, Emelie Curovic Rotbain, Caspar Da Cunha-Bang, Carsten Utoft Niemann, Christian Brieghel

Blood (2024) 144 (Supplement 1): 1860.

https://doi.org/10.1182/blood-2024-203046

Published: 2024

Journal Articles

Mutations in BCOR , CCND2 , NRAS and XPO1 Predict Clinical Outcomes upon MRD-Guided Venetoclax Plus Ibrutinib in Relapsed and Refractory Chronic Lymphocytic Leukemia

Christian Brieghel, Julie Dubois, Ida Kappel Buhl, Kazem Nasserinejad, Dennis De Rooij, Karl Nyrén, Hoa T Tran, Sabina Kersting, Mattias Mattsson, Juha Ranti, Rogier Mous, Gerrit Jan Veldhuis, Caspar da Cunha-Bang, Mark-David Levin, Valtteri Wirta, Richard Rosenquist, Arnon P. Kater, Carsten Utoft Niemann

Blood (2024) 144 (Supplement 1): 586.

https://doi.org/10.1182/blood-2024-204532

Published: 2024

Journal Articles

Quality of Life in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia Improves after Minimal Residual Disease-Guided Treatment with Ibrutinib Plus Venetoclax

Blood (2024) 144 (Supplement 1): 888.

https://doi.org/10.1182/blood-2024-211226

Published: 2024

Journal Articles

Epcoritamab Monotherapy in Patients (Pts) with Relapsed or Refractory (R/R) Chronic Lymphocytic Leukemia (CLL): Results from CLL Expansion and Optimization Cohorts of Epcore CLL-1

Blood (2024) 144 (Supplement 1): 883.

https://doi.org/10.1182/blood-2024-199708

Published: 2024

Journal Articles

NOTCH1 Mutations Are Associated with Therapy-Resistance in Patients with B-Cell Lymphoma Treated with CD20xCD3 Bispecific Antibodies

Emil Ramsø Kyvsgaard, Morten Grauslund, Lene Sjö, Linea Melchior, Trine Grantzau, Lise Mette Gjerdrum, Trine Trab, Lærke Sloth Andersen, Anne Ortved Gang, Marie Fredslund Breinholt, Michael Boe Møller, Jacob Haaber Christensen, Thomas Stauffer Larsen, Michael Roost Clausen, Anna Caroline Hasselbalch Riley, Carsten Utoft Niemann, Kirsten Gronbaek, Martin Hutchings, Simon Husby

Blood (2024) 144 (Supplement 1): 1594.

https://doi.org/10.1182/blood-2024-204772

Published: 2024

Journal Articles

Implementing Revised Reference Intervals for Free Light Chains Improves Risk Stratification of Monoclonal Gammopathy of Undetermined Significance

Cecilie Velsø Mæng, Sæmundur Rögnvaldsson, Thorir Long, Christian Brieghel, Carsten Utoft Niemann, Kirsten Gronbaek, Sigurdur Y Kristinsson, Sigrun Thorsteinsdottir

Blood (2024) 144 (Supplement 1): 3306.

https://doi.org/10.1182/blood-2024-201327

Published: 2024

Journal Articles

Patient-Reported Quality of Life Outcomes with Venetoclax-Based First-Line Combinations in CLL: An Analysis from the Phase 3 GAIA/CLL13 Trial

Blood (2024) 144 (Supplement 1): 3238.

https://doi.org/10.1182/blood-2024-198917

Published: 2024

Journal Articles

Venetoclax-obinutuzumab for previously untreated chronic lymphocytic leukemia: 6-year results of the randomized phase 3 CLL14 study

Blood (2024) 144 (18): 1924–1935.

https://doi.org/10.1182/blood.2024024631

Published: 2024

Includes: Supplemental data

Journal Articles

Reassessing the chronic lymphocytic leukemia International Prognostic Index in the era of targeted therapies

Blood (2024) 143 (25): 2588–2598.

https://doi.org/10.1182/blood.2023022564

Published: 2024

Includes: Supplemental data

Journal Articles

The Impact of Fitness and Dose Intensity on Safety and Efficacy Outcomes after Venetoclax-Obinutuzumab in Previously Untreated Chronic Lymphocytic Leukemia

Blood (2023) 142 (Supplement 1): 4639.

https://doi.org/10.1182/blood-2023-188827

Published: 2023

NARROW

In-Depth Immune and Metabolic Profiling of GAIA/CLL13 Patients to Uncover Treatment-Specific Changes to the T-Cell Compartment

Improved Innate Immune Function upon Preemptive Short-Term Acalabrutinib and Venetoclax in Newly Diagnosed CLL Patients with High Risk of Infections: Translational Findings from the Prevent-Acall Clinical Trial

Informative Censoring in Randomized First-Line Trials of Chronic Lymphocytic Leukemia

Telomere Length Associations with Characteristics and Outcome in Patients Treated with Venetoclax-Based First-Line Combinations in the GAIA/CLL13 Study

Ibrutinib-Rituximab Is Superior to Rituximab-Chemotherapy in Previously Untreated Older Mantle Cell Lymphoma Patients: Results from the International Randomised Controlled Trial, Enrich

Improved Efficacy with Response- and MRD-Guided Ibrutinib-Obinutuzumab (IO) Intensification after Ibrutinib-Venetoclax (IV) in First Line Chronic Lymphocytic Leukemia (CLL) Patients: Primary Analysis of the HOVON 158/Next STEP Phase 2 Trial

Acalabrutinib and Rituximab in Elderly Patients with Newly Diagnosed Mantle Cell Lymphoma Including a Matched Population-Based External Comparator- the Nordic Lymphoma Group NLG-MCL8 (ALTAMIRA) Phase II Trial

First-Line Ibrutinib Plus Venetoclax Vs Chlorambucil Plus Obinutuzumab in Elderly or Comorbid Patients (Pts) with Chronic Lymphocytic Leukemia (CLL): Glow Study 64-Month Follow-up (FU) and Adverse Event (AE)-Free Progression-Free Survival (PFS) Analysis

Machine Learning for Prediction of Serious Infections in Patients with Treatment-Naïve Lymphoma; A Population-Based Study of 701 Patients from the North Denmark Region

Safety of Venetoclax Ramp-up before CD20 Antibody Administration in Chronic Lymphocytic Leukemia

Excellent Clinical Outcomes in Deeply Mutated IGHV Chronic Lymphocytic Leukemia upon Fludarabine and Cyclophosphamide Plus Rituximab

Mutations in BCOR , CCND2 , NRAS and XPO1 Predict Clinical Outcomes upon MRD-Guided Venetoclax Plus Ibrutinib in Relapsed and Refractory Chronic Lymphocytic Leukemia

Quality of Life in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia Improves after Minimal Residual Disease-Guided Treatment with Ibrutinib Plus Venetoclax

Epcoritamab Monotherapy in Patients (Pts) with Relapsed or Refractory (R/R) Chronic Lymphocytic Leukemia (CLL): Results from CLL Expansion and Optimization Cohorts of Epcore CLL-1

NOTCH1 Mutations Are Associated with Therapy-Resistance in Patients with B-Cell Lymphoma Treated with CD20xCD3 Bispecific Antibodies

Implementing Revised Reference Intervals for Free Light Chains Improves Risk Stratification of Monoclonal Gammopathy of Undetermined Significance

Patient-Reported Quality of Life Outcomes with Venetoclax-Based First-Line Combinations in CLL: An Analysis from the Phase 3 GAIA/CLL13 Trial

Venetoclax-obinutuzumab for previously untreated chronic lymphocytic leukemia: 6-year results of the randomized phase 3 CLL14 study

Reassessing the chronic lymphocytic leukemia International Prognostic Index in the era of targeted therapies

The Impact of Fitness and Dose Intensity on Safety and Efficacy Outcomes after Venetoclax-Obinutuzumab in Previously Untreated Chronic Lymphocytic Leukemia

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only